5.3 million people in Central America's most stable OECD democracy; the country that proved HPV vaccines work through the world's landmark population-based vaccine trial, a Nicoya Blue Zone centenarian population unique in the hemisphere, and near-universal CCSS healthcare coverage.
Costa Rica's research proposition is built on proven infrastructure, OECD regulatory credibility, and two globally unique research populations: the NCI–CCSS partnership has demonstrated that Costa Rica's near-universal healthcare system can enrol and follow large clinical research cohorts at world-standard quality levels; and the Nicoya Blue Zone provides the hemisphere's most studied longevity population for aging medicine research; a combination available nowhere else in Central America and matched by very few countries globally.
Ministerio de Salud pharmaceutical regulation with CONIS national research ethics coordination; institutional CEC ethics committees at all major CCSS and private research hospitals; ICH GCP E6(R2)-aligned framework; OECD membership since May 2021; Central America's first and only OECD member; driving regulatory modernisation benchmarked against international standards; CAFTA-DR regulatory cooperation framework with US FDA creating favourable bilateral pharmaceutical regulatory context; improving CONIS review timelines as OECD alignment advances.
Per-patient and operational costs substantially below US and EU equivalents; competitive with Panama for the Central American OECD quality tier; CCSS near-universal coverage (~93–95%) provides the patient pre-identification infrastructure that reduces clinical trial screening overhead to the lowest of any Central American market; CRC moderately stable for USD-budgeted programs (USD widely accepted in Costa Rican business); Central America's most developed CRO and SMO infrastructure providing competitive service rates; GAM concentration of hospitals reduces intra-country monitoring travel costs.
5.3M with ~93–95% CCSS coverage creating structured patient access proven at scale in the CVT's 99.6% eligible enrollment rate; NCI–CCSS cancer prevention research cohorts actively maintained for ongoing cancer vaccine and prevention trial enrollment; Nicoya Blue Zone centenarian population for longevity, aging medicine, and cardiovascular prevention research; elevated gastric cancer rates (H. pylori-driven) for GI oncology programs; dengue-endemic Pacific coast and Caribbean lowlands for vaccine and antiviral trials; Afro-Costa Rican Limón community for Afro-Caribbean pharmacogenomics; growing urban NCD (cardiovascular, diabetes, obesity) burden through CCSS registry.
Hospital CIMA San José (HCA-affiliated, JCI-accredited; the only HCA hospital in Central America); Clínica Bíblica (established private research hospital with decades of international pharmaceutical partnerships); three major CCSS tertiary hospitals in the GAM (México, San Juan de Dios, Calderón Guardia); national specialty hospitals for paediatric, women's, and geriatric research; INCIENSA (population health research institute); Hospital Nacional de Geriatría connected to Nicoya longevity research; growing IQVIA and ICON presence; Juan Santamaría Airport direct connections to Miami, Houston, New York, and major US pharmaceutical hubs.
The Gran Área Metropolitana (GAM) concentrates Costa Rica's research infrastructure in a compact urban corridor; the CCSS tertiary hospitals (México, San Juan de Dios, Calderón Guardia), national specialty hospitals, and the GAM's established private institutions (CIMA, Clínica Bíblica, Hospital La Católica) all within 30 minutes of Juan Santamaría International Airport. The Guanacaste corridor provides access to the Nicoya Blue Zone and its longevity research populations, while the Puntarenas Pacific coast and Limón Caribbean coast extend Costa Rica's research geography into tropical disease-endemic and Afro-Caribbean population zones.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Hospital CIMA San José | San José | Costa Rica's most internationally sophisticated private hospital; affiliated with HCA Healthcare (Hospital Corporation of America), the world's largest private hospital operator, and holding JCI international accreditation; and the country's most active Phase II–IV commercial research institution; oncology, cardiovascular, metabolic disease, CNS, and internal medicine trial activity; Hospital CIMA's HCA affiliation is the only one of its kind in Central America, creating a clinical research culture whose quality management systems, documentation standards, and pharmaceutical company relationship protocols are directly comparable to HCA hospital research departments in the United States; the HCA connection provides continuous access to the US pharmaceutical industry's established hospital research partnership infrastructure, making CIMA the highest-quality private research institution between Mexico City and Bogotá for sponsors seeking US healthcare system-equivalent research execution in Central America. |
| 02 | Clínica Bíblica | San José | One of Costa Rica's oldest and most internationally connected private hospitals; founded in 1929 by the Latin American Mission (now a humanitarian healthcare institution) and maintaining a long tradition of international medical partnership; with an active Phase II–IV commercial research portfolio across oncology, cardiovascular, metabolic disease, and infectious disease; Clínica Bíblica's research department has been Costa Rica's most consistently active private commercial trial site across pharmaceutical industry partnerships, with established CEI ethics infrastructure and investigator experience in multinational Phase II–III protocol management; its English-language institutional heritage and international medical missionary connections create research documentation capacity and pharmaceutical company communication standards that reflect Central America's most internationally experienced private clinical research environment outside the CIMA/HCA system. |
| 03 | Hospital México (CCSS) | San José | One of Costa Rica's three major CCSS tertiary general hospitals in the GAM; the primary cardiovascular and haematology reference centre within the CCSS system; and an active Phase II–III commercial research site across cardiovascular disease, haematology, oncology, and internal medicine; Hospital México's cardiovascular surgery and interventional cardiology departments have been among Costa Rica's most productive for cardiovascular Phase II–III trials, and its position within the CCSS network provides research access to the large and continuously registered CCSS insured population across the GAM's most densely populated northern corridor; a critical CCSS public hospital site for sponsors requiring both cardiovascular and haematology research access through the Costa Rican public health system. |
| 04 | Hospital San Juan de Dios (CCSS) | San José | One of Costa Rica's oldest continuously operating hospitals; founded in 1845; and a major CCSS tertiary reference hospital in San José's historic centre with active Phase II–III research across oncology (particularly gastric cancer and colorectal cancer reflecting Costa Rica's elevated GI cancer rates), cardiovascular, metabolic disease, and internal medicine; Hospital San Juan de Dios' oncology department has been one of Costa Rica's most important for gastric cancer and colorectal cancer research, reflecting its NCI-affiliated cancer research tradition and the elevated gastric cancer incidence in the Costa Rican population; its central GAM location and CCSS affiliation provide patient access to San José's most demographically diverse urban catchment, encompassing the full spectrum of Costa Rican mestizo, indigenous-migrant, and Afro-Costa Rican urban populations. |
| 05 | Hospital Dr. Rafael Ángel Calderón Guardia (CCSS) | San José | The third major CCSS tertiary hospital in the GAM; named after the founding president of the CCSS itself; and a significant Phase II–III commercial research site across neurology, rheumatology, oncology, endocrinology, and internal medicine; Hospital Calderón Guardia's neurology and rheumatology departments have been among Costa Rica's most active for CNS and inflammatory disease Phase II–III programmes, and its position as the CCSS's primary GAM reference hospital for neurology provides access to the largest concentration of neurological disease patients in the Costa Rican public healthcare system; an important CCSS complement to Hospital México and Hospital San Juan de Dios for sponsors designing Costa Rica multi-site CCSS Phase III networks requiring patient coverage across the full GAM catchment. |
| 06 | Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera" (CCSS) | San José | Costa Rica's national children's hospital; the CCSS's paediatric reference centre for the entire country; and the primary site for paediatric Phase II–III clinical research; active in paediatric infectious disease (including dengue, respiratory viruses, and enteric disease programs), haematology, oncology, and paediatric cardiology; Hospital Nacional de Niños was a key paediatric site for the NCI-affiliated HPV natural history and vaccine immunogenicity studies in adolescent populations, and its CCSS affiliation gives it access to the systematic paediatric patient registry that makes population-based paediatric trial enrollment feasible at a scale unavailable in other Central American paediatric hospitals; an essential site for sponsors developing paediatric vaccines, dengue prophylaxis in children, or paediatric oncology programs requiring a population-registered Central American paediatric research platform. |
| 07 | Hospital de las Mujeres "Dr. Adolfo Carit Eva" (CCSS) | San José | Costa Rica's national hospital for women's health; the CCSS's primary reference centre for obstetrics, gynaecology, and women's reproductive health; and the most active Costa Rican site for women's health Phase II–III trials including HPV-related disease programs, cervical cancer prevention, maternal-fetal medicine, and gynaecological oncology; Hospital de las Mujeres was the primary clinical site for the Costa Rica Vaccine Trial's cervical and gynaecological outcome assessment component, and its investigators maintain the longest active experience in the Americas with population-based HPV vaccine efficacy data collection; for any sponsor developing HPV-related cancer prevention programs, next-generation cervical cancer vaccines, or women's oncology prevention trials, Hospital de las Mujeres is the institutional home of the CVT legacy and the indispensable site for continuing this research line in Costa Rica. |
| 08 | Hospital Nacional de Geriatría y Gerontología (CCSS) | San José | Costa Rica's national geriatric and gerontology hospital; the only dedicated national geriatric research hospital in Central America; and the institutional bridge between the CCSS's healthcare infrastructure and the Nicoya Blue Zone longevity research programmes; Phase II–III activity across geriatric medicine, cardiovascular disease in elderly populations, Alzheimer's disease and dementia, Parkinson's disease, and metabolic disease in aging cohorts; the Hospital Nacional de Geriatría's collaboration with the CCSS's Nicoya Blue Zone follow-up studies; which have tracked Nicoya centenarian and near-centenarian cohorts for over two decades; makes it the primary clinical institutional partner for sponsors interested in developing longevity medicine research programmes or aging medicine interventions that require access to the hemisphere's most scientifically characterised exceptional longevity population. |
| 09 | Hospital La Católica | San José | A major Catholic private hospital in San José's northern residential zone; one of Costa Rica's most research-active private institutions; with Phase II–IV commercial trial activity across oncology, cardiovascular, metabolic disease, and respiratory indications; Hospital La Católica's research department maintains established commercial pharmaceutical company partnerships and an active CEI ethics committee with experience reviewing multinational Phase II–III protocols; its patient catchment from San José's northern middle-class and professional residential districts provides access to a well-educated, health-literate mestizo and White Costa Rican patient population whose trial compliance and follow-up retention rates reflect the culturally high healthcare engagement that characterized the CVT's exceptional enrollment outcomes; an important private hospital complement to the CCSS and CIMA systems for sponsors designing comprehensive San José multi-site Phase III designs. |
| 10 | Hospital Regional Enrique Baltodano Briceño | Liberia | The primary CCSS reference hospital for Guanacaste Province; Costa Rica's northwestern province encompassing the Nicoya Peninsula Blue Zone; and the clinical research gateway to the hemisphere's most scientifically documented centenarian population; Phase II–III activity across cardiovascular disease (reflecting the Nicoya region's paradoxically low cardiovascular mortality despite dietary and lifestyle risk factors; a subject of ongoing research), tropical disease (Chagas disease, leishmaniasis, and dengue are present in the drier Guanacaste lowlands), and internal medicine; Hospital Baltodano's geographic position as the CCSS hospital serving the Nicoya Peninsula municipalities of Nicoya, Hojancha, Nandayure, and Santa Cruz; the specific communities documented in Blue Zone centenarian research; makes it the primary hospital partner for any sponsor designing longevity medicine trials or cardiovascular prevention studies in the Nicoya population. |
| 11 | Hospital Monseñor Sanabria | Puntarenas | The primary CCSS reference hospital for Puntarenas Province on Costa Rica's Pacific coast; a major port province with significant tropical disease exposure from seasonal dengue, dengue haemorrhagic fever, and Chikungunya transmission in the hot Pacific lowlands; and a Phase II–III research site for infectious disease, cardiovascular, and internal medicine; Hospital Sanabria's Pacific coast location provides access to the tropical disease patient populations that are geographically separate from the temperate GAM's urban disease profile, and its CCSS catchment covers the Puntarenas coast's large mestizo and agricultural working-class population whose dengue exposure history and serological profile make them important Phase II dengue vaccine immunogenicity and challenge trial populations; the primary Pacific coastal site for sponsors requiring dengue and tropical disease Phase II–III enrollment outside the GAM metropolitan area. |
| 12 | Hospital Tony Facio Castro | Limón | The primary CCSS reference hospital for Limón Province on Costa Rica's Caribbean coast; and the primary clinical research institution serving Costa Rica's Afro-Costa Rican community, whose Jamaican and West Indian ancestry creates a genetically and culturally distinct Caribbean Afro-Atlantic population found nowhere else in Central America at comparable density; Phase II–III activity across infectious disease (dengue, leptospirosis, and gastrointestinal pathogens reflecting the humid Caribbean lowlands' tropical disease burden), cardiovascular, and internal medicine; Hospital Tony Facio's Limón Province location provides research access to the Afro-Costa Rican communities of the Caribbean coast; English Caribbean heritage, Jamaican-ancestry genetic profile, and distinct dietary and lifestyle patterns; creating a pharmacogenomic and cardiovascular research population that is genuinely unique within Costa Rica and within the broader Central American research landscape. |
Costa Rica's most internationally sophisticated private hospital; affiliated with HCA Healthcare (Hospital Corporation of America), the world's largest private hospital operator, and holding JCI international accreditation; and the country's most active Phase II–IV commercial research institution; oncology, cardiovascular, metabolic disease, CNS, and internal medicine trial activity; Hospital CIMA's HCA affiliation is the only one of its kind in Central America, creating a clinical research culture whose quality management systems, documentation standards, and pharmaceutical company relationship protocols are directly comparable to HCA hospital research departments in the United States; the HCA connection provides continuous access to the US pharmaceutical industry's established hospital research partnership infrastructure, making CIMA the highest-quality private research institution between Mexico City and Bogotá for sponsors seeking US healthcare system-equivalent research execution in Central America.
One of Costa Rica's oldest and most internationally connected private hospitals; founded in 1929 by the Latin American Mission (now a humanitarian healthcare institution) and maintaining a long tradition of international medical partnership; with an active Phase II–IV commercial research portfolio across oncology, cardiovascular, metabolic disease, and infectious disease; Clínica Bíblica's research department has been Costa Rica's most consistently active private commercial trial site across pharmaceutical industry partnerships, with established CEI ethics infrastructure and investigator experience in multinational Phase II–III protocol management; its English-language institutional heritage and international medical missionary connections create research documentation capacity and pharmaceutical company communication standards that reflect Central America's most internationally experienced private clinical research environment outside the CIMA/HCA system.
One of Costa Rica's three major CCSS tertiary general hospitals in the GAM; the primary cardiovascular and haematology reference centre within the CCSS system; and an active Phase II–III commercial research site across cardiovascular disease, haematology, oncology, and internal medicine; Hospital México's cardiovascular surgery and interventional cardiology departments have been among Costa Rica's most productive for cardiovascular Phase II–III trials, and its position within the CCSS network provides research access to the large and continuously registered CCSS insured population across the GAM's most densely populated northern corridor; a critical CCSS public hospital site for sponsors requiring both cardiovascular and haematology research access through the Costa Rican public health system.
One of Costa Rica's oldest continuously operating hospitals; founded in 1845; and a major CCSS tertiary reference hospital in San José's historic centre with active Phase II–III research across oncology (particularly gastric cancer and colorectal cancer reflecting Costa Rica's elevated GI cancer rates), cardiovascular, metabolic disease, and internal medicine; Hospital San Juan de Dios' oncology department has been one of Costa Rica's most important for gastric cancer and colorectal cancer research, reflecting its NCI-affiliated cancer research tradition and the elevated gastric cancer incidence in the Costa Rican population; its central GAM location and CCSS affiliation provide patient access to San José's most demographically diverse urban catchment, encompassing the full spectrum of Costa Rican mestizo, indigenous-migrant, and Afro-Costa Rican urban populations.
The third major CCSS tertiary hospital in the GAM; named after the founding president of the CCSS itself; and a significant Phase II–III commercial research site across neurology, rheumatology, oncology, endocrinology, and internal medicine; Hospital Calderón Guardia's neurology and rheumatology departments have been among Costa Rica's most active for CNS and inflammatory disease Phase II–III programmes, and its position as the CCSS's primary GAM reference hospital for neurology provides access to the largest concentration of neurological disease patients in the Costa Rican public healthcare system; an important CCSS complement to Hospital México and Hospital San Juan de Dios for sponsors designing Costa Rica multi-site CCSS Phase III networks requiring patient coverage across the full GAM catchment.
Costa Rica's national children's hospital; the CCSS's paediatric reference centre for the entire country; and the primary site for paediatric Phase II–III clinical research; active in paediatric infectious disease (including dengue, respiratory viruses, and enteric disease programs), haematology, oncology, and paediatric cardiology; Hospital Nacional de Niños was a key paediatric site for the NCI-affiliated HPV natural history and vaccine immunogenicity studies in adolescent populations, and its CCSS affiliation gives it access to the systematic paediatric patient registry that makes population-based paediatric trial enrollment feasible at a scale unavailable in other Central American paediatric hospitals; an essential site for sponsors developing paediatric vaccines, dengue prophylaxis in children, or paediatric oncology programs requiring a population-registered Central American paediatric research platform.
Costa Rica's national hospital for women's health; the CCSS's primary reference centre for obstetrics, gynaecology, and women's reproductive health; and the most active Costa Rican site for women's health Phase II–III trials including HPV-related disease programs, cervical cancer prevention, maternal-fetal medicine, and gynaecological oncology; Hospital de las Mujeres was the primary clinical site for the Costa Rica Vaccine Trial's cervical and gynaecological outcome assessment component, and its investigators maintain the longest active experience in the Americas with population-based HPV vaccine efficacy data collection; for any sponsor developing HPV-related cancer prevention programs, next-generation cervical cancer vaccines, or women's oncology prevention trials, Hospital de las Mujeres is the institutional home of the CVT legacy and the indispensable site for continuing this research line in Costa Rica.
Costa Rica's national geriatric and gerontology hospital; the only dedicated national geriatric research hospital in Central America; and the institutional bridge between the CCSS's healthcare infrastructure and the Nicoya Blue Zone longevity research programmes; Phase II–III activity across geriatric medicine, cardiovascular disease in elderly populations, Alzheimer's disease and dementia, Parkinson's disease, and metabolic disease in aging cohorts; the Hospital Nacional de Geriatría's collaboration with the CCSS's Nicoya Blue Zone follow-up studies; which have tracked Nicoya centenarian and near-centenarian cohorts for over two decades; makes it the primary clinical institutional partner for sponsors interested in developing longevity medicine research programmes or aging medicine interventions that require access to the hemisphere's most scientifically characterised exceptional longevity population.
A major Catholic private hospital in San José's northern residential zone; one of Costa Rica's most research-active private institutions; with Phase II–IV commercial trial activity across oncology, cardiovascular, metabolic disease, and respiratory indications; Hospital La Católica's research department maintains established commercial pharmaceutical company partnerships and an active CEI ethics committee with experience reviewing multinational Phase II–III protocols; its patient catchment from San José's northern middle-class and professional residential districts provides access to a well-educated, health-literate mestizo and White Costa Rican patient population whose trial compliance and follow-up retention rates reflect the culturally high healthcare engagement that characterized the CVT's exceptional enrollment outcomes; an important private hospital complement to the CCSS and CIMA systems for sponsors designing comprehensive San José multi-site Phase III designs.
The primary CCSS reference hospital for Guanacaste Province; Costa Rica's northwestern province encompassing the Nicoya Peninsula Blue Zone; and the clinical research gateway to the hemisphere's most scientifically documented centenarian population; Phase II–III activity across cardiovascular disease (reflecting the Nicoya region's paradoxically low cardiovascular mortality despite dietary and lifestyle risk factors; a subject of ongoing research), tropical disease (Chagas disease, leishmaniasis, and dengue are present in the drier Guanacaste lowlands), and internal medicine; Hospital Baltodano's geographic position as the CCSS hospital serving the Nicoya Peninsula municipalities of Nicoya, Hojancha, Nandayure, and Santa Cruz; the specific communities documented in Blue Zone centenarian research; makes it the primary hospital partner for any sponsor designing longevity medicine trials or cardiovascular prevention studies in the Nicoya population.
The primary CCSS reference hospital for Puntarenas Province on Costa Rica's Pacific coast; a major port province with significant tropical disease exposure from seasonal dengue, dengue haemorrhagic fever, and Chikungunya transmission in the hot Pacific lowlands; and a Phase II–III research site for infectious disease, cardiovascular, and internal medicine; Hospital Sanabria's Pacific coast location provides access to the tropical disease patient populations that are geographically separate from the temperate GAM's urban disease profile, and its CCSS catchment covers the Puntarenas coast's large mestizo and agricultural working-class population whose dengue exposure history and serological profile make them important Phase II dengue vaccine immunogenicity and challenge trial populations; the primary Pacific coastal site for sponsors requiring dengue and tropical disease Phase II–III enrollment outside the GAM metropolitan area.
The primary CCSS reference hospital for Limón Province on Costa Rica's Caribbean coast; and the primary clinical research institution serving Costa Rica's Afro-Costa Rican community, whose Jamaican and West Indian ancestry creates a genetically and culturally distinct Caribbean Afro-Atlantic population found nowhere else in Central America at comparable density; Phase II–III activity across infectious disease (dengue, leptospirosis, and gastrointestinal pathogens reflecting the humid Caribbean lowlands' tropical disease burden), cardiovascular, and internal medicine; Hospital Tony Facio's Limón Province location provides research access to the Afro-Costa Rican communities of the Caribbean coast; English Caribbean heritage, Jamaican-ancestry genetic profile, and distinct dietary and lifestyle patterns; creating a pharmacogenomic and cardiovascular research population that is genuinely unique within Costa Rica and within the broader Central American research landscape.
These are the primary regulatory, academic, and industry bodies shaping Costa Rica's clinical research ecosystem.
Costa Rica's Ministry of Health; the primary pharmaceutical regulatory authority for clinical trial authorisation; working through CONIS (Consejo Nacional de Investigación en Salud) to oversee, authorise, and coordinate national health research in accordance with the General Health Law, Ministry of Health regulations, and WHO GCP and ICH GCP E6(R2) standards; CONIS's review and authorisation processes have been progressively modernised under OECD accession requirements, improving regulatory predictability and review timelines; as the first Central American OECD member, Costa Rica's Ministerio de Salud's regulatory standards now serve as the regional benchmark for pharmaceutical regulation across the SICA bloc.
Costa Rica's national social security health insurance and healthcare delivery agency; founded in 1941 and covering approximately 93–95% of Costa Ricans through a unified insurance, hospital, and primary care system; and the institutional infrastructure that made the Costa Rica Vaccine Trial's 99.6% eligible enrollment rate possible; the CCSS's national hospital network, electronic patient registry, and CEI ethics committee system provide the structural patient access, identification, and follow-up capability that underpins all major Costa Rican clinical trial programs; CCSS's institutional research ethics committees at Hospital México, Hospital San Juan de Dios, and other major CCSS hospitals are among Costa Rica's most experienced for reviewing and approving multinational commercial Phase II–III trial protocols.
Costa Rica's Ministry of Science, Innovation, Technology, and Telecommunications; the government body funding and coordinating national research and innovation through competitive grants and strategic research priority programmes; MICITT's health research funding supports UCR Faculty of Medicine, INCIENSA, and CCSS-affiliated research programmes; its OECD-aligned innovation strategy; reflecting Costa Rica's commitment to knowledge-economy development post-OECD accession; creates the framework for public-private clinical research partnerships and the US-Costa Rica scientific collaboration agreements through which NCI and NIH-funded research programs engage Costa Rican academic and CCSS institutional investigators.
Costa Rica's primary public research university and the academic anchor of the national medical investigator pipeline; affiliated with CCSS teaching hospitals and producing the physician investigator community that staffs commercial Phase II–III trial activity across Costa Rica's public hospital research network; the UCR Faculty of Medicine's research programmes in oncology, tropical medicine, and public health have been the academic foundation of the NCI–CCSS research partnership; UCR's Clodomiro Picado Institute (ICP); one of the world's leading centres for antivenom research and production, whose polyvalent snake antivenom is used across Central and South America, sub-Saharan Africa, and Asia; demonstrates the depth of internationally recognised biomedical research capability that Costa Rica's public university system has sustained independent of its small population and income level.
Costa Rica's national institute for research and teaching in nutrition and health; a government biomedical and public health research institute conducting population-level disease surveillance, nutritional epidemiology, laboratory diagnostics, and clinical research across Costa Rica's four CCSS regions; INCIENSA's national cancer registry (RCNC; Registro Nacional de Tumores) provides the cancer incidence and survival data underlying oncology trial feasibility assessments across Costa Rica; its infectious disease surveillance laboratory network; including a WHO-affiliated reference laboratory for flavivirus and enterovirus characterisation; provides the epidemiological dengue, Zika, and arbovirus data that supports tropical disease Phase II–III vaccine and antiviral trial design in Costa Rica's endemic regions.
Costa Rica's largest private medical university; producing a significant proportion of the national physician workforce alongside UCR; with active research programmes in internal medicine, public health, and clinical pharmacology that contribute to the investigator pool for commercial Phase II–III trial activation across San José's private and CCSS hospital network; UCIMED's growing international academic partnerships and OECD-aligned curriculum development create an investigator pipeline whose research training quality has been progressively strengthened to meet the international GCP and regulatory standards required by multinational pharmaceutical company research partnerships.
UCR's internationally celebrated antivenom research and production institute; one of the world's leading centres for snakebite treatment research, producing polyvalent antivenoms used across Central America, sub-Saharan Africa, and Asia; whose expertise in venom pharmacology, antibody production, and Phase I–III antivenom clinical evaluation has established Costa Rica as a globally recognised reference centre for neglected tropical disease drug development; ICP's WHO collaborating centre status and its long research partnerships with the Liverpool School of Tropical Medicine, Wellcome Trust, and Médecins Sans Frontières demonstrate the international research credibility that Costa Rica's public research institutions have achieved across neglected disease areas; for sponsors developing snakebite antivenoms, venom toxin-targeting therapies, or animal toxin-derived pharmaceutical agents, ICP provides the world's most comprehensive venom pharmacology research environment outside specialised UK and Australian institutions.
Global CRO with Costa Rican operations managing Phase II–IV programs across oncology (cancer prevention, HPV-related programs, gastric cancer, colorectal), cardiovascular, infectious disease (dengue, vaccine programs), and metabolic disease indications; Ministerio de Salud/CONIS regulatory submission expertise and institutional CEC ethics application support; established site monitoring networks across Hospital CIMA, Clínica Bíblica, Hospital México, Hospital San Juan de Dios, and Hospital Calderón Guardia; CAFTA-DR regional network coordination pairing Costa Rican sites with Panamanian, Guatemalan, and Dominican Republic sites within integrated Central American and Caribbean Phase III designs; NCI partnership experience in CCSS-enrolled population-based trial management.
International CRO with Costa Rican operations supporting Phase II–IV oncology, vaccine, cardiovascular, and metabolic disease programs; established investigator relationships across the GAM's CCSS tertiary hospital network and private research institutions (CIMA, Clínica Bíblica, La Católica); specialist cancer prevention and HPV-related trial management reflecting Costa Rica's NCI research legacy; CONIS regulatory strategy for sponsors using Costa Rica as the cancer prevention or vaccine Phase II–III anchor of Central American regional programs; Nicoya Blue Zone longevity cohort access coordination for sponsors designing aging medicine or cardiovascular prevention studies in the Peninsula's centenarian communities.
Global CRO with Costa Rican operations providing Phase II–III trial management and Ministerio de Salud/CONIS regulatory strategy across oncology, cardiovascular, infectious disease, and metabolic indications; established site networks across GAM's CCSS and private hospital cluster; biostatistics and data management for Costa Rican-site trials with Afro-Costa Rican, mestizo, and indigenous ancestry pharmacogenomic sub-group analysis; Central American regional programme coordination spanning Costa Rica, Panama, and Guatemala within integrated Phase III designs for sponsors building complete CAFTA-DR corridor clinical development networks.
International biopharmaceutical solutions company with Costa Rican operations providing integrated Phase I–IV clinical development services across oncology, cardiovascular, vaccine, and metabolic disease; CONIS submission expertise and institutional CEC ethics committee navigation across GAM's CCSS and private hospital networks; specialist dengue and flavivirus vaccine trial management reflecting Costa Rica's tropical disease endemic profile and established vaccine platform capability from the CVT era; CAFTA-DR regional programme management coordinating Costa Rican sites within Central American multi-country Phase III designs for sponsors building the isthmus's most complete OECD-anchored research networks.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.